Evaluation of the preventive effect of skin disinfection using an alcohol preparation containing 1% chlorhexidine glucoronate against dialysis catheter-related infections

Hanyu, Rika; Fujimoto, Keiji; Ikeda, Asami; Iida, Emi; Yamaguchi, Yuriko; Maeda, Kazumi; Yokoyama, Hitoshi

doi:10.4009/jsdt.51.299

Cited by 1 publication

(1 citation statement)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The proportion of catheter-related infections in previous studies was approximately 6.3% with 1% chlorhexidine alcohol 15 ; no such data have been reported with OLG. However, the proportion of CRBSIs with 1% chlorhexidine alcohol is comparable to that with OLG in previous studies (unpublished data; 1% vs 0.9%).…”

Section: Methods and Analysismentioning

confidence: 99%

Efficacy and safety of 1.5% aqueous olanexidine gluconate antiseptic solution compared to 1% alcoholic chlorhexidine for the prevention of intravenous catheter-related infections (Apollo study): a protocol for a randomised controlled trial

et al. 2021

View full text Add to dashboard Cite

IntroductionChlorhexidine alcohol (1.0%–2.0%) is currently recommended as a skin disinfectant to be used prior to catheterisation for preventing catheter-related infections. However, chlorhexidine alcohol has various side effects and has little antibacterial effect on methicillin-resistant Staphylococcus aureus (MRSA). Therefore, MRSA remains a concern for catheter-related bloodstream infection (CRBSI) prevention. Olanedine, containing 1.5% olanexidine gluconate in aqueous solution, was developed in Japan in 2015 and is structurally similar to chlorhexidine. Olanexine has been used as a disinfectant against various gram-positive and gram-negative bacteria and MRSA. This study aims to compare the efficacy of 1.5% aqueous olanexidine gluconate and 1% chlorhexidine alcohol as skin antiseptics for the prevention of catheter-related infections.Methods and analysisThis Apollo study is an open-label, multicentre, non-inferiority, two-arm, parallel-group, randomised controlled trial conducted at 21 intensive care units (ICUs) and high-care units (HCUs) in Japan. All patients scheduled to be admitted to the ICU or HCU of a facility participating in this study, who require central venous catheter insertion are eligible. Eligible patients will be assigned to either the 1.5% aqueous olanexidine gluconate or 1% chlorhexidine alcohol group by randomisation in a ratio of 1:1 with stratification by centres. The antibacterial agents are to be used as a skin disinfectant before and during catheter placement. The primary endpoint is the proportion of catheter-related infections, defined as a composite of catheter-related sepsis without bacteraemia and CRBSI. A total of 1980 patients will be included in this study.Ethics and disseminationThis clinical trial was approved by the Institutional Review Board of Jichi Medical University and the ethics committees of the participating institutions. The study results will be disseminated through conferences, peer-reviewed publications and meetings with interested parties.Trial registration numberUniversity hospital Medical Information Network (registration ID: UMIN000042343). This registration includes all items in the WHO Trial Registration Data Set.Protocol versionThis protocol corresponds to the original protocol version 5.

show abstract

Section: Methods and Analysismentioning

confidence: 99%